%0 Journal Article
%T Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer
%A Kiyoshi Komuta
%A Seigo Minami
%A Shouichi Ihara
%A Shouko Ikuta
%J Archive of "World Journal of Oncology".
%D 2019
%R 10.14740/wjon1193
%X The Gustave Roussy Immune Score (GRIm-Score) and the Royal Marsden Hospital prognostic score (RMH score) were recently developed in order to improve a better participant selection for phase I trials. The GRIm-Score is formed by combination of lactate dehydrogenase (LDH), serum albumin concentration, and neutrophil-to-lymphocyte ratio (NLR). The RMH score is calculated by LDH, albumin, and number of metastases. These two scores have been validated only in phase I trials. The purpose of this study was to assess whether these scores are useful for practical treatment of immune-checkpoint inhibitor (ICI) monotherapy in pretreated non-small cell lung cancer (NSCLC)
%K Gustave Roussy Immune Score
%K Royal Marsden Hospital prognostic score
%K Immune-checkpoint inhibitor
%K Nivolumab
%K Pembrolizumab
%K Atezolizumab
%K Pretreated
%K Non-small cell lung cancer
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497012/